Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
Saved in:
| Title: | Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. |
|---|---|
| Authors: | Mathieu C; Katholieke Universiteit Leuven, Leuven, Belgium. chantal.mathieu@uzleuven.be., Catrinoiu D; Spitalul Clinic Judetean de Urgenta Constanta, Constanţa, Romania., Ranetti AE; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Johnsson E; AstraZeneca Gothenburg, Mölndal, Sweden., Hansen L; Bristol-Myers Squibb, Princeton, NJ, USA., Chen H; AstraZeneca, Gaithersburg, MD, USA., Garcia-Sanchez R; AstraZeneca, Gaithersburg, MD, USA., Iqbal N; AstraZeneca, Gaithersburg, MD, USA., Celiñski A; CenterMed-Centrum Badań Klinicznych, Kraków, Poland. |
| Source: | Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2018 Aug; Vol. 9 (4), pp. 1703-1711. Date of Electronic Publication: 2018 May 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1869-6953 |
|---|---|
| DOI: | 10.1007/s13300-018-0445-x |
